Business Wire

Alliance to End Plastic Waste Partners with ASASE Foundation

7.5.2020 14:00:00 EEST | Business Wire | Press release

Share

The Alliance to End Plastic Waste (the Alliance) today announced a partnership with the ASASE Foundation to support women entrepreneurs working to reduce plastic litter in the community. The initiative called Closing the Loop uses a circular economy model to enable local communities to benefit from discarded plastic waste by collecting, reprocessing and reselling it.

Closing the Loop kicks off the Alliance’s support for projects based in Africa. It was first launched by ASASE in 2018 to provide seed money to equip a plastic waste reprocessing plant and offer technical and business management training to women entrepreneurs to run the recycling plant for profit. In the first twelve months, the project created eight jobs within the community and diverted 35 (metric) tons of plastic from waste. By partnering with the Alliance, the capacity of the reprocessing plant will increase to divert 2,000 (metric) tons of plastic waste per year and create even more jobs.

“A key pillar of ending plastic waste in the environment is the sustainable impact it will bring to the well-being of local communities. Our partnership with ASASE is especially meaningful because Closing the Loop is the right step towards a circular economy model. It directly benefits those living in areas which don’t have access to plastic waste collection and sorting systems. This initiative is a simple but scalable action, supporting the inspiring women of Ghana who are building communities towards a path to end plastic waste in the environment,” said Jacob Duer, President and CEO, Alliance to End Plastic Waste.

“What we value most in our partnership with the Alliance to End Plastic Waste is the access to the expertise in waste management, which we can leverage now in our project, effectively multiplying the impact of the funding provided by the Alliance to our project,” comments Dana Mosora, ASASE Foundation Founder and Managing Director.

The partnership has also opened the possibility to bring in expertise from academic partner, the Swiss Federal Institute of Technology, in areas of developing new end market applications and concepting a new financing system for the management of plastic waste in Ghana.

The recycling plant processes a range of plastic waste from water sachets (LDPE) to shampoo and detergent bottles (HDPE) and large cooking oil containers (HDPE), converting it into regrinds. The regrinds are then sold to recyclers to make items such as pavement blocks, sheets for construction and basins and liners, most of which goes back into the community.

About:

The Alliance to End Plastic Waste is a not-for-profit organization bringing together industry, government, communities, and civil society in the fight to end plastic waste.

ASASE Foundation enables Ghanaian women entrepreneurs to play a key role in cashing-in on the plastic waste trash of Accra for the benefit of their own communities.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lianne Mason
+65 91002437
Lianne.mason@endplasticwaste.org

Cassandra Cheong
+65 9827 2056
Cassandra.cheong@endplasticwaste.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye